Amgen Inc. (AMGN) To Go Ex-Dividend on February 13th

Amgen Inc. (NASDAQ:AMGN) declared a quarterly dividend on Tuesday, December 9th. Stockholders of record on Friday, February 13th will be paid a dividend of 2.52 per share by the medical research company on Friday, March 6th. This represents a c) annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, February 13th. This is a 5.9% increase from Amgen’s previous quarterly dividend of $2.38.

Amgen has increased its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 14 consecutive years. Amgen has a dividend payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 47.1%.

Amgen Trading Down 3.0%

NASDAQ:AMGN opened at $364.65 on Wednesday. The firm has a market capitalization of $196.36 billion, a P/E ratio of 25.63, a P/E/G ratio of 3.85 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a fifty day moving average of $335.74 and a 200 day moving average of $312.39. Amgen has a 52 week low of $261.43 and a 52 week high of $385.12.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen will post 20.62 earnings per share for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.